who we serve
Trusted by Innovators Across the Ecosystem Empowering Digital Health Innovators Worldwide:
Health Intel Global partners with organizations at the forefront of digital health transformation. From agile startups to enterprise-scale healthcare leaders, we provide targeted expertise and execution support to navigate regulatory complexity, accelerate clinical validation, and unlock market readiness. Our services are tailored to each client’s stage, scale, and strategic objectives.
Clients Types:
- AI Health Startups Building SaMD Platforms
We work with early- and growth-stage companies developing Software as a Medical Device (SaMD) products powered by AI and machine learning. Whether you’re preparing a de novo 510(k), validating model performance, or integrating with EMRs, we help bridge the gap between innovation and regulatory acceptance. - Biotech Teams Embedding Diagnostics
For molecular, genomic, and biomarker-driven biotech firms, we provide advisory and technical services to integrate digital diagnostics and companion algorithms into their therapeutic ecosystems. Our support spans clinical study design, FDA interactions, and digital endpoint strategy. - Medtech Players Expanding into Digital Realms
Traditional device manufacturers are increasingly integrating connected software, AI analytics, and real-world data platforms. We help medtech teams plan and execute their digital expansion—whether through embedded firmware, companion apps, or post-market evidence generation. - Health-Tech Investors & Incubators
We collaborate with venture capital firms, corporate incubators, and digital health accelerators to evaluate technology pipelines, assess regulatory and reimbursement risk, and support portfolio companies in building credible clinical and go-to-market narratives - Health Systems & Pilot Project Consortia
For academic medical centers, provider networks, and testbed consortia exploring new care models, we offer design and implementation support for pilots, including protocol development, IRB alignment, outcome selection, and partner interfacing. Our focus is on evidence generation that translates into scalable, reimbursable innovation.